{
  "id": 8896872,
  "title": "Belgium’s Novadip Biosciences raises €10.4 million to fund pivotal clinical trial and unlock EIB loan tranche",
  "url": "https://urgent.news/2026/09/21/belgiums-novadip-biosciences-raises-10-4-million-to-fund-pivotal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-21T09:40:43.000Z",
  "source": {
    "name": "EU-Startups",
    "slug": "eu-startups",
    "url": "https://www.eu-startups.com/2026/09/belgiums-novadip-biosciences-raises-e10-4-million-to-fund-pivotal-clinical-trial-and-unlock-eib-loan-tranche/"
  },
  "original_language": "en",
  "account": "Belgian biotech Novadip Biosciences has raised €10.4 million in convertible financing to support a pivotal Phase 3 clinical trial for its regenerative medicine product, NVD003. Led by US venture firm New Science Ventures, the round brings total convertible funding to €20 million since June 2025. Novadip, founded in 2013, develops a proprietary 3M³ platform that uses a patient's own stem cells in a 3D extracellular matrix to regenerate bone. The NVD003 trial, currently underway in the US and EU, aims to treat congenital pseudarthrosis of the tibia (CPT), a rare pediatric bone condition. Successful completion of the trial and FDA approval could bring a Rare Pediatric Disease Priority Review Voucher worth over $100 million. The funding will also help Novadip prepare a US Biologics License Application and pursue strategic partnerships.",
  "summary": "Novadip Biosciences, a Belgian late-stage clinical BioTech company specialising in regenerative medicine, has closed a €10.4 million (roughly $12 million) convertible financing round. The round was led by US-based New Science Ventures, with participation from a syndicate of Novadip’s existing backers, including Fund+, Wallonie Entreprendre, VIVES Fund, ORSA Tech, Sambrinvest, Noshaq and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}